17,261 trials
Schizophrenia and Predominant Negative Symptoms
Primary: Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried…
Glioma · Medulloblastoma
Primary: Percentage of Participants With Objective Response of Complete Response or Partial Response — 32.6; 0 percentage of participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels — -85.7; -117.4; -99.6 mg/dL — p=0.002
Kidney Cancer
Primary: Maximum Tolerated Dose (MTD) of Erlotinib Hydrochloride When Used in Combination With Sunitinib. — 50; 150 milligrams
Waldenstrom's Macroglobulinemia
Primary: Overall Response (OR) Rate — 38 percentage of patients
Adult Meningioma
Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 0 Participants
Lung Cancer, Non-Small Cell
Primary: Progression-free Survival (PFS) — 25.0; 22.9 weeks — p=0.2647
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Serologic Response (Change in CA125 Level) — 2 participants
Congenital Heart Disease
Primary: Number of Subjects Reporting Adverse Events Through Study Day 150 — 575; 566 participants
Pancreatic Cancer
Primary: Median Overall Survival (OS) — 42 months
Lymphoma
Primary: Disease-free Survival (DFS) — 11.33; 9.635 months
Type 2 Diabetes Mellitus
Primary: Mean Change From Baseline in Plasma HbA1c (Glycosylated Hemoglobin / Hemoglobin A1c) — -0.38; -0.26; -0.25; -0.30 percent
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Epilepsy · Epilepsy, Generalized · Seizures
Primary: Percent Reduction in Number of Drop Seizures. — 10.1; 85.2 Percent Reduction — p=<0.0182
HIV Infections · H1N1 Influenza Virus
Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 113; 0; 7; 6 participants